Results 41 to 50 of about 11,064 (108)

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Volume 78, Issue 6, Page 761-770, June 2026.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source

Osmolality‐Independent Impact of Sodium on Glycosylation of an Fc‐Fusion Protein and the Hexosamine Biosynthesis Pathway in a Chinese Hamster Ovary Cell Line

Biotechnology Journal, Volume 21, Issue 6, June 2026.
Graphical Abstract and Lay Summary Sodium and potassium supplementation in CHO batch culture elevates intracellular UDP‐HexNAc concentrations through activation of the hexosamine biosynthesis pathway (HBP), independently of osmolality. Increased nucleotide sugar availability enhances Fc‐fusion protein glycosylation and reduces the abundance of low ...
Jason Reiniger, Adrian Pöttner, Lara Rosenberger, Aline Zimmer   +3 more
wiley   +1 more source

Oral lichenoid lesions in CTLA‐4 haploinsufficiency: Targeting IFN‐γ‐driven mucosal immunopathology

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Chen Wang, Laurie Brenchley, Teresa Greenwell‐Wild, Vasileios Ionas Theofilou, Timothy G. Myers, Chi A. Ma, Katherine Howe, Stefania Pittaluga, Steven M. Holland, Niki M. Moutsopoulos, David Fraser, Gulbu Uzel   +11 more
wiley   +1 more source

Association of Body Mass Index with SARS‐CoV‐2 Infection in Inflammatory Arthritis Patients Receiving Biologic Therapy: Singapore National Biologics Register Findings

International Journal of Rheumatic Diseases, Volume 29, Issue 6, June 2026.
ABSTRACT Purpose To determine the association of body mass index (BMI) with incident COVID‐19 infection in patients with inflammatory arthritis (IA) using biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) and to describe characteristics of patients with severe COVID‐19 infection. Methods This prospective
Preeti Dhanasekaran, Siaw Ing Yeo, Yi Xin Ng, Rosa Lim, Stephanie Wong, Stanley Angkodjojo, Andrew Yu Keat Khor, Li Wearn Koh, Manjari Lahiri, Margaret Ma   +9 more
wiley   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Two decades of biologic and JAK inhibitor prescription patterns in the western region of Melbourne

Internal Medicine Journal, Volume 56, Issue 6, Page 1059-1067, June 2026.
Abstract Background and Aim Safety concerns and medication shortages may influence prescribing practices in rheumatology. This study aimed to explore the impact of Janus kinase inhibitor (JAKi) safety warnings and the COVID‐19 pandemic on biologic and targeted‐synthetic disease‐modifying antirheumatic drug (b/tsDMARD) prescription patterns from 2002 to
Alexander Kwan, Elvina Ingrid, Sara Vogrin, Ken Luong, Fei Jin, Emma Brown, Dongzhe Li, Matthew Jiang, Keith K. T. Lim   +8 more
wiley   +1 more source

Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology

Pediatric Allergy and Immunology, Volume 37, Issue 6, June 2026.
This graphical abstract illustrates the conceptual framework linking rare and common diseases in pediatric allergy and immunology through precision medicine. On the left, rare conditions such as inborn errors of immunity and primary atopic disorders represent well‐defined monogenic models that reveal fundamental mechanisms of immune dysregulation.
Riccardo Castagnoli, Martina Votto, Ivan Taietti, Maria Isabel Delgado‐Dolset, Rubén Fernández‐Santamaría, Martha Jimenez Freites, Mattia Giovannini, Mark Kačar, Aspasia Karavelia, Janice Layhadi, Urszula Radzikowska, Cezmi A. Akdis, Mubeccel Akdis, Marketa Bloomfield, Francesco Cinetto, Antoine Deschildre, Jonathan Hourihane, Susanne Lau, Antonio Nieto‐Garcia, Ismail Ogulur, Liam O'Mahony, Mohamed Shamji, Milena Sokolowska, Maria Jose Torres, Sophia Tsabouri, Philippe Eigenmann, on behalf of the EAACI‐Clemens von Pirquet Foundation   +26 more
wiley   +1 more source

A homozygous CTLA-4 variant causes CTLA-4 deficiency with severe immune dysregulation. [PDF]

J Hum Immun
Catak MC, Can S, Hubrack S, Bayram Catak F, Elmi A, Babayeva R, Amirov R, Yorgun Altunbas M, Bilgic Eltan S, Ertem D, Yilmaz B, Koc A, Erman B, Bozkurtlar E, Karakoc-Aydiner E, Ozen A, Lo B, Baris S.   +17 more
europepmc   +1 more source

Cancer risk associated with abatacept among older individuals with rheumatoid arthritis in the United States. [PDF]

JNCI Cancer Spectr
Ahmed S, Mariette X, Seror R, Engels EA.
europepmc   +1 more source